|Bid||0.000 x 100000|
|Ask||0.000 x 100000|
|Day's Range||10.291 - 10.568|
|52 Week Range||7.767 - 21.180|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pour consulter la lettre d'information; cliquez sur le lien: http://share.thomsonreuters.com/assets/newsletters/Morning_News_Call/MNCCA_FR_08082017.pdf PRINCIPAUX INDICATEURS À L’AGENDA Pas d’indicateurs ...
Pour consulter la lettre d'information; cliquez sur le lien: http://share.thomsonreuters.com/assets/newsletters/Morning_News_Call/MNCCA_FR_05092017.pdf PRINCIPAUX INDICATEURS À L’AGENDA 08:30 Permis de ...
Valeant is so focused on extending its debt maturities and lowering its debt levels that it's ignored its two biggest issues.
Valeant Pharmaceuticals Intl Inc (NYSE: VRX ) filed its 2016 10-K on March 3, resulting in pressure on shares. Valeant's disclosures are concerning and the business trends remain weak, which would likely ...
Pharmaceutical and biotech company Valeant Pharma (VRX) slipped down 4.33% to $12.50 intraday Monday due to an announcement of debt restructuring.
Valeant Pharmaceuticals International Inc plans to line up a US$3.06bn incremental term loan and junk bond sale as part of a debt restructuring, sources said. In addition to the new debt offering, the company paid down about US$1.1bn of senior secured term loans with proceeds from the sale of its skincare products assets on March 3, according to a Monday regulatory filing. Valeant is also repaying a portion of its 6.75% senior notes due in 2018 and extending the maturity date of its revolving credit facility with the proceeds from the new loan and a secured high-yield bond.
Valeant Pharmaceuticals announced that it intends to refinance some of its debt. One key analyst thinks that this might be a sign to abandon ship.
Here's the good news: Valeant Pharmaceuticals has raised $1.1 billion dollars in asset sales it...
Valeant Pharmaceuticals International (VRX) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.
TheStreet's Action Alerts PLUS portfolio manager Jim Cramer discusses the day's most talked about stocks every morning on our Facebook Live show.
Valeant Pharmaceuticals shares hit a multiyear low this past week, and some analysts took this opportunity to reevaluate their stance on the stock.
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
On February 23rd EyeGate (EYEG) reported financial results for their fourth quarter ending December 31st. The company reported an additional $160k of collaboration revenue related to government grants which are funding some of Jade’s pipeline candidates. In September 2016 EYEG announced that they were awarded an additional $448k from the U.S. Department of Defense, which represents the second year of funding under an SBIR grant related to the development of CMHA-S as an ocular bandage (“OBG”). Approximately $445k remains under the current grants which run through 2017 and which is reflected in our model as revenue in the current year. Q4 operating expenses were $3.9M, up slightly from the $3.6M in Q3 but below our $4.1M estimate. The difference from our estimate relates to lower SG&A expense. Meanwhile, R&D continues to trend at about $2.5M, which includes clinical trial costs related to progress of EGP-437 in the phase III study for anterior uveitis as well as the phase 1b/2a study in cataract surgery. Additionally, the OBG pilot study in PRK recently completed.